Lara Meisner's most recent trade in Bicara Therapeutics Inc. was a trade of 90,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bicara Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | 02 Feb 2026 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.24 per share. | 29 Sep 2025 | 33,807 | 33,807 | - | 9.2 | 312,495 | Common Stock |
| Bicara Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | 29 Sep 2025 | 33,807 | 101,423 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 14.75 per share. | 29 Sep 2025 | 33,807 | 0 | - | 14.7 | 498,653 | Common Stock |
| Bicara Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.45 per share. | 15 Sep 2025 | 15,829 | 15,829 | - | 5.4 | 86,268 | Common Stock |
| Bicara Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 11.49 per share. | 15 Sep 2025 | 15,829 | 0 | - | 11.5 | 181,875 | Common Stock |
| Bicara Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | 15 Sep 2025 | 9,744 | 87,699 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | 15 Sep 2025 | 6,085 | 54,769 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 10.43 per share. | 16 Jun 2025 | 15,829 | 0 | - | 10.4 | 165,096 | Common Stock |
| Bicara Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.45 per share. | 16 Jun 2025 | 15,829 | 15,829 | - | 5.4 | 86,268 | Common Stock |
| Bicara Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | 16 Jun 2025 | 9,744 | 97,443 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | 16 Jun 2025 | 6,085 | 60,854 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.45 per share. | 14 Mar 2025 | 79,146 | 79,145 | - | 5.5 | 431,346 | Common Stock |
| Bicara Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | 14 Mar 2025 | 48,720 | 107,187 | - | - | Stock Option (Right to Buy) | ||
| Bicara Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 12.69 per share. | 14 Mar 2025 | 48,526 | 30,620 | - | 12.7 | 615,698 | Common Stock |
| Bicara Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 13.24 per share. | 14 Mar 2025 | 30,620 | 0 | - | 13.2 | 405,513 | Common Stock |
| Bicara Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | 14 Mar 2025 | 30,246 | 67,119 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.03 per share. | 15 Jun 2023 | 2,269 | 32,240 (0%) | 0% | 23.0 | 52,255 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | 15 Jun 2023 | 2,269 | 37,481 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 28.02 per share. | 15 Jun 2023 | 2,269 | 29,971 (0%) | 0% | 28.0 | 63,577 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | 15 Jun 2023 | 28 | 37,453 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 28.33 per share. | 15 Jun 2023 | 27 | 29,971 (0%) | 0% | 28.3 | 765 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.04 per share. | 15 Jun 2023 | 27 | 29,998 (0%) | 0% | 23.0 | 622 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.51 per share. | 02 Jun 2023 | 5,126 | 35,097 (0%) | 0% | 18.5 | 94,882 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | 02 Jun 2023 | 5,126 | 84,375 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 25.02 per share. | 02 Jun 2023 | 5,126 | 29,971 (0%) | 0% | 25.0 | 128,253 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | 02 Jun 2023 | 1,875 | 18,128 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 24.21 per share. | 02 Jun 2023 | 1,875 | 29,971 (0%) | 0% | 24.2 | 45,394 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 02 Jun 2023 | 1,875 | 31,846 (0%) | 0% | 14 | 26,250 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | 02 Jun 2023 | 499 | 89,501 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 25.03 per share. | 02 Jun 2023 | 499 | 29,971 (0%) | 0% | 25.0 | 12,490 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.51 per share. | 02 Jun 2023 | 499 | 30,470 (0%) | 0% | 18.5 | 9,236 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 29.07 per share. | 09 Mar 2023 | 29,971 | 0 (0%) | 0% | 29.1 | 871,257 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | 08 Feb 2023 | 108,000 | 108,000 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 35.66 per share. | 23 Jan 2023 | 6,843 | 0 (0%) | 0% | 35.7 | 244,021 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.03 per share. | 23 Jan 2023 | 4,971 | 4,971 (0%) | 0% | 23.0 | 114,482 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | 23 Jan 2023 | 4,971 | 39,750 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 23 Jan 2023 | 1,872 | 6,843 (0%) | 0% | 14 | 26,208 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | 23 Jan 2023 | 1,872 | 20,003 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | 20 Dec 2022 | 16,326 | 44,721 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 29.19 per share. | 20 Dec 2022 | 16,326 | 0 (0%) | 0% | 29.2 | 476,556 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.03 per share. | 20 Dec 2022 | 16,326 | 16,326 (0%) | 0% | 23.0 | 375,988 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.03 per share. | 20 Dec 2022 | 600 | 600 (0%) | 0% | 23.0 | 13,818 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | 20 Dec 2022 | 600 | 61,047 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 28.07 per share. | 20 Dec 2022 | 600 | 0 (0%) | 0% | 28.1 | 16,842 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 28.44 per share. | 15 Dec 2022 | 1,297 | 0 (0%) | 0% | 28.4 | 36,887 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | 15 Dec 2022 | 1,297 | 61,647 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.03 per share. | 15 Dec 2022 | 1,297 | 1,297 (0%) | 0% | 23.0 | 29,870 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | 15 Dec 2022 | 300 | 62,944 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 28.08 per share. | 15 Dec 2022 | 300 | 0 (0%) | 0% | 28.1 | 8,424 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.03 per share. | 15 Dec 2022 | 300 | 300 (0%) | 0% | 23.0 | 6,909 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | 12 Dec 2022 | 15,656 | 63,244 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 28.12 per share. | 12 Dec 2022 | 15,656 | 0 (0%) | 0% | 28.1 | 440,247 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.03 per share. | 12 Dec 2022 | 15,656 | 15,656 (0%) | 0% | 23.0 | 360,558 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 28.05 per share. | 12 Dec 2022 | 600 | 0 (0%) | 0% | 28.1 | 16,830 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | 12 Dec 2022 | 600 | 78,900 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.03 per share. | 12 Dec 2022 | 600 | 600 (0%) | 0% | 23.0 | 13,818 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 22.05 per share. | 15 Nov 2022 | 8,125 | 0 (0%) | 0% | 22.0 | 179,156 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 15 Nov 2022 | 8,125 | 8,125 (0%) | 0% | 14 | 113,750 | Common Stock |
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | 15 Nov 2022 | 8,125 | 21,875 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Lara Meisner | General Counsel and Secretary | 02 Feb 2022 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) |